Drug Trial Radar · NCT05442216
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
May 1, 2024
Primary completion
Jul 21, 2030
Study completion Jul 21, 2031
Sponsor
- Lead sponsor
- Joshua ZeidnerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stemline Therapeutics, Inc.; University of North Carolina, Chapel Hill
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A treatment cycle is 28 days. Tagraxofusp will be administered at 9 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 3 consecutive days (or 3 doses over a period not to exceed 10 days if postponement is required to allow for toxicity resolution), followed by azacitidine administered at 75 mg/m2 SQ or IV daily on Day 4 through Day 10. Venetoclax will begin on Day 4 and continue through Day 24 (21 consecutive days). A bone marrow biopsy (BM Bx) will be performed on Day 24 (+3 days) of Cycle 1. Subjects who do not achieve a CRm will proceed with the next cycle of Induction Phase study treatment, irrespective of hematologic laboratory values. Cycle 2+ will consist of tagraxofusp 9 mcg/kg IV over 15 minutes daily for 3 consecutive days (Day 1-3 or 3 doses over a period not to exceed 10 days if postponement is required to allow for toxicity resolution), azacitidine 75 mg/m2 SQ or IV on Day 1 through Day 7 or Days 1-7 or 1-5, 8-9 and venetoclax 400 mg daily Day 1 through Day 21. A bone marrow biopsy (BM Bx) will be performed on Day 21 (+3 days) of Cycle 2. If a CRm is obtained or maintained, the subject will move to or remain on the Continuation Phase. Subjects who do not achieve a marrow CR (CRm) after Cycle 2 will proceed with the next cycle of Induction Phase study treatment as described above, irrespective of hematologic laboratory values. If a CRm is obtained after Cycle 3 or 4, the subject will move to the Continuation Phase . If a CRm is not obtained after Cycle 4, study treatment will be discontinued and the subject will move to follow up. If per the investigator, the subject is receiving clinical benefit, study treatment may continue until toxicity or completion of 12 total cycles. A BM Bx will be performed at least every 3 cycles for these subjects.
Conditions
- Acute Myeloid Leukemia
Interventions
TagraxofuspDrug
9 mcg/kg intravenously Days 1-3
AzacitidineDrug
75 mg/m2 subcutaneously or intravenously Days 1-7
VenetoclaxDrug
400 mg daily Days 1-21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete ResponseTime frame: 5 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Recruiting
AdventHealth Orlando
Orlando, Florida · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina · Recruiting
Penn Medicine Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Lifespan Health System Rhode Island Hospital
Providence, Rhode Island · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.